Favre H
Département de médicine, Hôpital cantonal universitaire, Genève.
Schweiz Med Wochenschr. 1989 Jun 17;119(24):868-71.
The cost/benefit ratio of renal biopsy defines the mandatory indications in situations where histologic diagnosis is required for the choice of treatment and for predicting the evolution of renal function. These indications include nephrotic syndrome, permanent proteinuria associated with microhematuria or not, rapidly progressive nephropathies, and, at least in some authors' view, systemic lupus erythematosus. Additional indications should be considered in patients presenting with acute renal failure of unknown origin, renal involvement accompanying systemic diseases, isolated microhematuria and intermittent proteinuria. In these latter indications histology allows the choice of specific therapy in some 20% of cases; the evolution of renal function can be correctly evaluated in 90% of cases. Patients usually consider renal biopsy a benign investigation which helps them to cope with their disease on the basis of a definite diagnosis.
肾活检的成本效益比决定了在需要组织学诊断以选择治疗方案和预测肾功能演变的情况下的强制指征。这些指征包括肾病综合征、伴有或不伴有镜下血尿的持续性蛋白尿、快速进展性肾病,并且至少在一些作者看来,还包括系统性红斑狼疮。对于不明原因急性肾衰竭、伴有全身性疾病的肾脏受累、孤立性镜下血尿和间歇性蛋白尿的患者,应考虑其他指征。在这些后者指征中,组织学检查在约20%的病例中有助于选择特定治疗;在90%的病例中可以正确评估肾功能的演变。患者通常认为肾活检是一项良性检查,有助于他们在明确诊断的基础上应对疾病。